Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Cyclo [Arg-Gly-Asp-D-Phe-Val]

Integrin inhibitor
 
BML-AM100-0001 1 mg 103.00 USD
Do you need bulk/larger quantities?
 
Integrin αvβ3 antagonist. Inhibits cell adhesion events mediated by αvβ3. Inhibits angiogenesis. Induces rapid regression of histologically distinct human tumors. Induces apoptosis of angiogenic blood vessels.

Product Specification

Sequence:Cyclo[Arg-Gly-Asp-D-Phe-Val]
 
Formula:C26H38N8O7 . HOAc . 0.5H2O
 
MW:643.7
 
CAS:137813-35-5
 
Purity:≥98%
 
Appearance:Lyophilized solid.
 
Solubility:Soluble in DMSO (5 mg/ml) and PBS (1 mg/350μl).
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Regulatory Status:RUO - Research Use Only
 
bml-am100
Please mouse over
bml-am100

Product Literature References

Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling: D.M. Cedano Prieto, et al.; PLoS One 12, e0184285 (2017), Application(s): Inhibition of beta3-CHO cell binding to IGF2, Abstract; Full Text
Testing the efficacy of Contrast Enhanced Ultrasound in detecting transplant rejection using a murine model of heart transplantation: K. Fischer, et al.; Am. J. Transplant. 17, 1791 (2017), Abstract;
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels: P.C. Brooks, et al.; Cell 79, 1157 (1994), Abstract;
Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1: M. Aumailley, et al.; FEBS Lett. 291, 50 (1991), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
Integrin
CD51
CD61
By biological activity:
Integrin Inhibitor
CD51 Inhibitor
CD61 Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
Keep in touch

©2020 Enzo Life Sciences, Inc.,